Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGRX-678 vs Investigator Selected TKI in CML-CP Patients Resistant or Intolerant to >=3 TKIs
NCT07489755Phase 3Not yet recruiting
- Sponsor
- Shenzhen TargetRx
- Start
- Apr 2026
- Primary completion
- May 2030
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of TGRX-678 in chronic myelogenous leukemia (CML), sponsored by Shenzhen TargetRx. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
TGRX-678
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT07489755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489755.